Adherence to Capecitabine Among Patients With Gastrointestinal Cancer: A Prospective Cohort Study

Adherence to Capecitabine Among Patients With Gastrointestinal Cancer: A Prospective Cohort Study

Adherence to capecitabine, an effective oral chemotherapy agent, is essential in achieving treatment response in cancer. In this study, we aimed to investigate factors associated with non-adherence to capecitabine in a sample of patients with gastrointestinal cancer. We enrolled 98 patients with co...

Full description

Bibliographic Details
Main Authors:	Ahmad Khajeh-Mehrizi, Seyed Amir Hossein Emami, Seyed Reza Safaee Nodehi, Zahra Jahangard-Rafsanjani, Kamran Roudini, Mohammad Reza Dabiri, Seyed Amir Mahdi Emami
Format:	Article
Language:	English
Published:	Tehran University of Medical Sciences 2023-01-01
Series:	Acta Medica Iranica
Subjects:	Capecitabine Adherence Gastrointestinal cancer Oral chemotherapy Side effects
Online Access:	https://acta.tums.ac.ir/index.php/acta/article/view/10051

Similar Items

Adherence and safety study in patients on treatment with capecitabine
by: Francisca Fernández-Ribeiro, et al.
Published: (2017-03-01)

A Rare Case on Capecitabine Induced Acquired Palmoplantar Keratoderma
by: Tsaqilah L, et al.
Published: (2023-12-01)

Capecitabine-associated gastrointestinal ulceration, haemorrhage, and obstruction: a pharmacovigilance analysis based on the FAERS
by: Yuwei Wang, et al.
Published: (2024-06-01)

Adherence and patients’ experiences with the use of capecitabine in daily practice
by: Lonneke Timmers, et al.
Published: (2016-09-01)

Management of severe capecitabine-induced corneal toxicity
by: Mathieu Heyvaert, et al.
Published: (2024-12-01)

Adherence to oral antineoplastic therapy
by: R. Olivera-Fernandez, et al.
Published: (2014-04-01)

Effect of capecitabine on breast cancer patients with different estrogen receptor status
by: Gang Xu, et al.
Published: (2020-04-01)

Severe ileum bleeding following adjuvant capecitabine chemotherapy for locally advanced colon cancer: a case report and review of the literature
by: You Zou, et al.
Published: (2021-11-01)

Relapsed urachal carcinoma responding to first‐line chemotherapy with capecitabine‐oxaliplatin plus bevacizumab
by: Akihiko Hatano, et al.
Published: (2023-11-01)

Advanced adrenocortical carcinoma successfully treated with gemcitabine plus capecitabine as second‐line chemotherapy
by: Akinaru Yamamoto, et al.
Published: (2020-11-01)

Chemo-immune cell therapy by intratumoral injection of adoptive NK cells with capecitabine in gastric cancer xenograft model
by: Zeinab Ghazvinian, et al.
Published: (2023-09-01)

Capecitabine and Temozolomide (CAPTEM) in Advanced Neuroendocrine Neoplasms (NENs): A Systematic Review and Pooled Analysis
by: Arrivi G, et al.
Published: (2022-12-01)

Capecitabine versus 5-fluorouracil in colorectal cancer: where are we now?
by: Lakshmi Chintala, et al.
Published: (2011-06-01)

Assessment of Oral Capecitabine in Elderly Patients with Stage 2 Colon Cancer: Toxicity, Tolerability, and Survival Outcomes
by: Ezgi Değerli, et al.
Published: (2024-11-01)

Cost-effectiveness analysis of metronomic capecitabine as adjuvant chemotherapy in locoregionally advanced nasopharyngeal carcinoma
by: Longjiang She, et al.
Published: (2022-09-01)

Chemotherapy increases CDA expression and sensitizes malignant pleural mesothelioma cells to capecitabine treatment
by: Darya Karatkevich, et al.
Published: (2024-08-01)

Cisplatin combined with capecitabine-induced chemotherapy for local nasopharyngeal carcinoma can improve the quality of life and reduce toxic and side effects
by: Ying Gao, et al.
Published: (2021-09-01)

Oral vinorelbine and capecitabine as first-line therapy in metastatic breast cancer: a retrospective analysis
by: Maria Rosaria Valerio, et al.
Published: (2021-12-01)

Hormonal therapy might be a better choice as maintenance treatment than capecitabine after response to first-line capecitabine-based combination chemotherapy for patients with hormone receptor-positive and HER2-negative, metastatic breast cancer
by: Xue-Lian Chen, et al.
Published: (2016-04-01)

Nonplatinum‐based therapy with Paclitaxel and Capecitabine for advanced squamous cell carcinomas of the anal canal: A population‐based Danish anal cancer group study
by: Christina Glismand Truelsen, et al.
Published: (2021-05-01)

Hypofractionated radiotherapy concomitant to capecitabine after induction chemotherapy for advanced pancreatic adenocarcinoma
by: Paolo Passoni, et al.
Published: (2024-07-01)

Capecitabine-induced activation of actinic keratosis: A common but underrecognized adverse event
by: Samantha Marley, et al.
Published: (2021-03-01)

Randomized phase II study of capecitabine plus cisplatin with or without sorafenib in patients with metastatic gastric cancer (STARGATE)
by: Min‐Hee Ryu, et al.
Published: (2023-04-01)

A phase II study of neoadjuvant capecitabine, oxaliplatin, and irinotecan (XELOXIRI) in patients with locally advanced rectal cancer
by: Chu Matsuda, et al.
Published: (2023-01-01)

Effect of the duration of the capecitabine regimen following colon cancer surgery in an elderly population: a retrospective cohort study
by: Weiwei Chen, et al.
Published: (2021-08-01)

Clinical Prognostic Factors in Patients With Metastatic Adrenocortical Carcinoma Treated With Second Line Gemcitabine Plus Capecitabine Chemotherapy
by: Salvatore Grisanti, et al.
Published: (2021-02-01)

Evaluation of Outcome and Tolerability of Combination Chemotherapy with Capecitabine and Oxaliplatin as First Line Therapy in Advanced Gastric Cancer
by: Mohammad Ali Mashhadi, et al.
Published: (2016-10-01)

Rs11479 in Thymidine Phosphorylase Associated with Prognosis of Patients with Colorectal Cancer Who Received Capecitabine-Based Adjuvant Chemotherapy
by: Jia X, et al.
Published: (2023-03-01)

Real-world efficacy and safety of capecitabine with oxaliplatin in patients with advanced adenocarcinoma of the ampulla of Vater
by: Seunghwan Lee, et al.
Published: (2024-05-01)

Effect of Different Durations of Adjuvant Capecitabine Monotherapy on the Outcome of High-Risk Stage II and Stage III Colorectal Cancer: A Retrospective Study Based on a CRC Database
by: Qiao Yu, et al.
Published: (2023-01-01)

Oral Maintenance Chemotherapy Using S-1/Capecitabine in Metastatic Nasopharyngeal Carcinoma Patients After Systemic Chemotherapy: A Single-Institution Experience
by: Guo Q, et al.
Published: (2020-02-01)

A pilot study investigating plasma pharmacokinetics and tolerance of oral capecitabine in carcinoma-bearing dogs
by: Sarah Wetzel, et al.
Published: (2024-01-01)

Capecitabine-Related Fourth Nerve Palsy: A Case Report
by: Marco Rocco Pastore, et al.
Published: (2024-04-01)

Oral Maintenance Chemotherapy Using S-1/Capecitabine in Metastatic Nasopharyngeal Carcinoma Patients After Systemic Chemotherapy: A Single-Institution Experience [Corrigendum]
by: Guo Q, et al.
Published: (2020-03-01)

Safety and efficacy of irinotecan, oxaliplatin, and capecitabine (XELOXIRI) regimen with or without targeted drugs in patients with metastatic colorectal cancer: a retrospective cohort study
by: Xiu Liu, et al.
Published: (2022-07-01)

A phase II study of a doublet metronomic chemotherapy regimen consisting of oral vinorelbine and capecitabine in Chinese women with HER2‐negative metastatic breast cancer
by: Yue Chai, et al.
Published: (2023-08-01)

Capecitabine-based chemotherapy in early-stage triple-negative breast cancer: a meta-analysis
by: Jie Bai, et al.
Published: (2023-10-01)

The Clinical Value of Chemotherapy Combined With Capecitabine in Triple-Negative Breast Cancer—A Meta-Analysis
by: Zilin Zhang, et al.
Published: (2021-11-01)

Survival of GEJ and gastric adenocarcinoma patients admitted at Imam Khomeini and Aram oncology clinic and treated with preoperative EOX chemotherapy
by: ALI FARAHAT, et al.
Published: (2023-06-01)

Efficacy and Safety of Capecitabine for Triple-Negative Breast Cancer: A Meta-Analysis
by: Xueqiong Xun, et al.
Published: (2022-07-01)